Form 4: Corcept Therapeutics Insider Trades Common Stock

Gary Charles Robb, Chief Business Officer at Corcept Therapeutics Inc., reported a transaction involving common stock on May 27, 2026.

Summary

• Gary Charles Robb, Chief Business Officer at Corcept Therapeutics Inc., reported a transaction on May 27, 2026.
• The transaction involved the acquisition of 600 shares of common stock at a price of $0.00.
• Following this transaction, Robb beneficially owns 25,081 shares directly.
• Additionally, Robb has indirect beneficial ownership of 12,571 shares in a custodial account for a child, another 12,571 shares in a custodial account for a child, and 49,716 shares held by the Gary Charles Robb TTE Robb Revocable Trust.
• The filing also notes unvested restricted stock awards granted on various dates between September 2, 2025, and June 1, 2026, which are subject to vesting conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions and stock awards rather than significant financial performance or strategic shifts.

Positives

• The reporting person acquired additional shares of common stock.
• The acquisition of 600 shares was at no cost, indicating a potential award or grant.

Risks

• The filing mentions unvested restricted stock awards which are subject to vesting requirements, implying potential forfeiture if conditions are not met.

Future Outlook

The filing details unvested restricted stock awards with future vesting dates, contingent upon the reporting person satisfying certain requirements.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company officers and directors. These filings are crucial for investors seeking to understand insider sentiment and potential shifts in beneficial ownership.

Related Party Transactions

• Indirect beneficial ownership is reported through custodial accounts for a child and a revocable trust where the reporting person is trustee.

Stakeholder Impact

• Shareholders gain insight into the direct and indirect holdings of a key executive.
• Employees may observe executive compensation practices through the reporting of restricted stock awards.

Next Steps

• Vesting of restricted stock awards based on anniversary of grant dates and satisfaction of requirements.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Common Stock, Beneficial Ownership, Restricted Stock Awards, Gary Charles Robb